Nocturia Market Report 2026

The nocturia market size has grown strongly in recent years. It will grow from $3.1 billion in 2025 to $3.35 billion in 2026 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to aging population growth, increased incidence of benign prostatic hyperplasia, rising prevalence of urinary tract infections, widespread use of diuretic medications, limited early diagnostic awareness.

The nocturia market size is expected to see strong growth in the next few years. It will grow to $4.51 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to growing demand for personalized treatment, expansion of home care therapies, increasing healthcare expenditure, rising focus on sleep quality management, improved access to urology specialists. Major trends in the forecast period include rising geriatric population and age-related urological disorders, increasing prevalence of diabetes and metabolic disorders, growing awareness and diagnosis of lower urinary tract symptoms, shift toward combination drug therapies, expansion of home-based nocturia management.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the nocturia market in the coming years. Cardiovascular diseases (CVDs) encompass a range of disorders affecting the heart and blood vessels, including heart disease, stroke, and hypertension. Their rising incidence is linked to factors such as aging populations, sedentary lifestyles, unhealthy diets, smoking, excessive alcohol consumption, obesity, high blood pressure, high cholesterol, diabetes, and genetic predisposition. Patients with cardiovascular conditions frequently experience nocturia as a symptom, which increases the demand for effective diagnosis and treatment solutions. As these conditions continue to grow globally due to aging populations and lifestyle factors, the need for nocturia management is expected to expand. For example, in September 2025, according to the British Heart Foundation, a UK-based charity, over 7.6 million people in the UK - more than 4 million men and 3.6 million women - are living with cardiovascular disease. Projections suggest that, driven by an aging population and improved survival rates, the number of affected individuals could rise by around 1 million by 2030 and approximately 2 million by 2040. Therefore, the growing burden of cardiovascular diseases is contributing to the expansion of the nocturia market.

Major companies operating in the nocturia market are focusing on the development of innovative products, such as orally disintegrating tablets (ODTs), to improve patient convenience and adherence to treatment. Orally disintegrating tablets are solid dosage forms that dissolve rapidly in the mouth without the need for water, making them suitable for patients who have difficulty swallowing. For instance, in July 2024, Adalvo Limited, a Malta-based pharmaceutical company, launched Desmopressin ODT in Europe to treat conditions that cause excessive fluid loss, including central cranial diabetes insipidus. This synthetic vasopressin tablet manages excessive thirst, frequent urination, and bedwetting by mimicking the natural hormone and reducing water excretion in urine. It is also used to control bleeding in mild to moderate hemophilia A and von Willebrand disease by promoting the release of blood clotting factors.

In March 2023, KYORIN Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, entered into a licensing partnership with Sumitomo Pharma to commercialize the overactive bladder therapy vibegron in Taiwan, Hong Kong, Singapore, Indonesia, and Vietnam for an undisclosed amount. Through this agreement, KYORIN aims to expand the regional reach of its β3-adrenergic receptor agonist by leveraging Sumitomo Pharma’s expertise in development, manufacturing, and commercialization across high-growth Asian markets. Sumitomo Pharma is a Japan-based company specializing in pharmaceutical research, development, and commercialization solutions, with a strategic focus on therapies addressing unmet medical needs.

Major companies operating in the nocturia market are Pfizer Inc, Merck & Co. Inc, AbbVie Inc, Sanofi S.A, GlaxoSmithKline plc, Viatris Inc, Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd, Astellas Pharma Inc, Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd, Ferring Pharmaceuticals A/S, Avadel Pharmaceuticals plc, UroGen Pharma Ltd, Sanwa Kagaku Co. Ltd., Urovant Sciences Inc, Serenity Pharmaceuticals LLC, Vantia Therapeutics Inc, AA Pharma Inc, Wellesley Pharmaceuticals Inc.

North America was the largest region in the nocturia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nocturia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nocturia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the nocturia market by increasing costs for imported active pharmaceutical ingredients, medical-grade excipients, and drug manufacturing equipment, leading to pricing pressures for branded and generic therapies. These impacts are most pronounced in drug segments such as desmopressin and anticholinergics, and in regions reliant on cross-border pharmaceutical supply chains, particularly Asia-Pacific and parts of Europe. Tariff-related cost escalation has also slowed hospital procurement and limited affordability in home care settings. However, tariffs have encouraged local drug manufacturing, regional supply chain diversification, and increased investment in domestic pharmaceutical production, creating long-term resilience for the market.

The nocturia market research report is one of a series of new reports that provides nocturia market statistics, including nocturia industry global market size, regional shares, competitors with a nocturia market share, detailed nocturia market segments, market trends and opportunities, and any further data you may need to thrive in the nocturia industry. This nocturia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nocturia is a medical condition characterized by the need to wake up one or more times during the night to urinate. It is classified as a lower urinary tract symptom (LUTS) and may result from various underlying causes, including excessive fluid intake before bedtime, overactive bladder, urinary tract infections, diabetes, or prostate enlargement in men. Nocturia can negatively affect sleep quality and overall health, leading to fatigue and reduced daytime productivity.

The primary drugs for treating nocturia include anticholinergic drugs, desmopressin, antibiotics, antispasmodics, and other medications. Anticholinergic drugs work by blocking acetylcholine to reduce involuntary bladder contractions, helping manage overactive bladder and nocturia. Key clinical indications for these medications include mixed nocturia, low nocturnal bladder capacity, nocturnal polyuria, and global polyuria. Causes of nocturia can include urological infections, bladder tumors, diuretic use, regular alcohol or coffee consumption, liver disorders, diabetes, pregnancy, and other factors. These drugs are utilized by end users such as hospitals, clinics, and homecare settings.

The nocturia market consists of revenues earned by entities by providing services such as diagnostic services, pharmacological treatment services, behavioral therapy and lifestyle modification services and telemedicine and remote consultation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The nocturia market also includes sales of bladder control devices, alpha-blockers, diuretics, and tricyclic antidepressants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.